

Wan-Teck Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4624122/publications.pdf>

Version: 2024-02-01

172
papers

9,515
citations

50244

46
h-index

40954

93
g-index

184
all docs

184
docs citations

184
times ranked

15124
citing authors

#	ARTICLE	IF	CITATIONS
1	Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. <i>Nature</i> , 2018, 557, 575-579.	13.7	942
2	Isolation and retrieval of circulating tumor cells using centrifugal forces. <i>Scientific Reports</i> , 2013, 3, 1259.	1.6	618
3	A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. <i>Nature Medicine</i> , 2012, 18, 521-528.	15.2	510
4	Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. <i>Lab on A Chip</i> , 2014, 14, 128-137.	3.1	485
5	Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	0.8	345
6	Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. <i>Journal of Clinical Oncology</i> , 2006, 24, 2245-2251.	0.8	334
7	Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742). <i>Journal of Clinical Oncology</i> , 2018, 36, 1412-1418.	0.8	324
8	Genomic landscape of lung adenocarcinoma in East Asians. <i>Nature Genetics</i> , 2020, 52, 177-186.	9.4	281
9	Methionine is a metabolic dependency of tumor-initiating cells. <i>Nature Medicine</i> , 2019, 25, 825-837.	15.2	226
10	Concurrent Chemo-Radiation With or Without Induction Gemcitabine, Carboplatin, and Paclitaxel: A Randomized, Phase 2/3 Trial in Locally Advanced Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 952-960.	0.4	197
11	Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. <i>Nature Medicine</i> , 2021, 27, 1536-1543.	15.2	197
12	Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients. <i>Biosensors and Bioelectronics</i> , 2010, 26, 1701-1705.	5.3	191
13	Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma. <i>Molecular Therapy</i> , 2014, 22, 132-139.	3.7	185
14	An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. <i>Analyst</i> , The, 2014, 139, 3245-3255.	1.7	173
15	Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells. <i>PLoS ONE</i> , 2014, 9, e99409.	1.1	165
16	Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. <i>Cancer</i> , 2015, 121, 1599-1607.	2.0	163
17	Novel therapeutic targets on the horizon for lung cancer. <i>Lancet Oncology</i> , The, 2016, 17, e347-e362.	5.1	156
18	Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression. <i>Nature Communications</i> , 2016, 7, 11702.	5.8	155

#	ARTICLE	IF	CITATIONS
19	A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3179-3184.	1.8	148
20	Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. <i>Nature Medicine</i> , 2017, 23, 1167-1175.	15.2	141
21	Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing. <i>Nature Communications</i> , 2018, 9, 216.	5.8	136
22	The Impact of Smoking Status on the Behavior and Survival Outcome of Patients With Advanced Non-small Cell Lung Cancer. <i>Chest</i> , 2004, 126, 1750-1756.	0.4	127
23	Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol [®] -PM) in patients with solid tumors. <i>Annals of Oncology</i> , 2010, 21, 382-388.	0.6	119
24	IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. <i>Journal of Thoracic Oncology</i> , 2022, 17, 309-323.	0.5	114
25	A phase II study evaluating the safety and efficacy of an adenovirus- β 1-LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2012, 23, 997-1005.	0.6	110
26	Microfluidic enrichment for the single cell analysis of circulating tumor cells. <i>Scientific Reports</i> , 2016, 6, 22076.	1.6	109
27	A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 5481-5489.	3.2	96
28	An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. <i>Nature Communications</i> , 2017, 8, 1734.	5.8	95
29	Clonal <i>MET</i> Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 876-884.	0.8	91
30	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215.	0.9	79
31	Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2005, 103, 569-575.	2.0	77
32	Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer). <i>Annals of Oncology</i> , 2017, 28, 2698-2706.	0.6	77
33	Liquid biopsy: one cell at a time. <i>Npj Precision Oncology</i> , 2019, 3, 23.	2.3	72
34	Advances in systemic treatment for nasopharyngeal carcinoma. <i>Chinese Clinical Oncology</i> , 2016, 5, 21-21.	0.4	69
35	The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1471-1478.	1.1	67
36	Genomic Profiles Specific to Patient Ethnicity in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2011, 17, 3542-3550.	3.2	65

#	ARTICLE	IF	CITATIONS
37	Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma. <i>Annals of Oncology</i> , 2011, 22, 718-722.	0.6	64
38	Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial. <i>Annals of Oncology</i> , 2020, 31, 789-797.	0.6	62
39	Concordance of anaplastic lymphoma kinase (<i>ALK</i>) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 23251-23262.	0.8	61
40	Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma. <i>Cancer</i> , 2008, 113, 1332-1337.	2.0	58
41	Pan-cancer analysis connects tumor matrisome to immune response. <i>Npj Precision Oncology</i> , 2019, 3, 15.	2.3	58
42	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014, 35, 1267-1275.	1.3	57
43	EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients. <i>Journal of Thoracic Oncology</i> , 2017, 12, 529-538.	0.5	57
44	A Randomized Phase II Trial of Single-Agent Gemcitabine, Vinorelbine, or Docetaxel in Patients with Advanced Non-small Cell Lung Cancer Who Have Poor Performance Status and/or Are Elderly. <i>Journal of Thoracic Oncology</i> , 2007, 2, 230-236.	0.5	54
45	Single-Cell Analysis of Circulating Tumor Cells: Why Heterogeneity Matters. <i>Cancers</i> , 2019, 11, 1595.	1.7	53
46	Addressing cellular heterogeneity in tumor and circulation for refined prognostication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 17957-17962.	3.3	51
47	Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. <i>British Journal of Cancer</i> , 2005, 93, 23-28.	2.9	50
48	Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. <i>Cancer Science</i> , 2020, 111, 536-547.	1.7	44
49	Bosutinib inhibits migration and invasion via <i>ack1</i> in <i>kras</i> mutant non-small cell lung cancer. <i>Molecular Cancer</i> , 2014, 13, 13.	7.9	42
50	Intertumor heterogeneity of non-small cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics. <i>International Journal of Cancer</i> , 2014, 135, 1092-1100.	2.3	41
51	Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9067-9067.	0.8	41
52	Lung cancer in never-smokers. <i>Journal of Clinical Pathology</i> , 2006, 60, 337-340.	1.0	39
53	Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6413-6423.	3.2	37
54	Correlation between Epidermal Growth Factor Receptor Mutations and Expression of Female Hormone Receptors in East-Asian Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2010, 5, 17-22.	0.5	35

#	ARTICLE	IF	CITATIONS
55	Molecular Profiling for Druggable Genetic Abnormalities in Carcinoma of Unknown Primary. <i>Journal of Clinical Oncology</i> , 2013, 31, e237-e239.	0.8	31
56	Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079). <i>Investigational New Drugs</i> , 2015, 33, 985-991.	1.2	31
57	Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2520-2520.	0.8	31
58	Influence of <i>SLCO1B3</i> haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 606-618.	1.1	30
59	Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1928-1934.	0.5	30
60	Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. <i>Cancers</i> , 2020, 12, 1025.	1.7	30
61	Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>PLoS ONE</i> , 2015, 10, e0123587.	1.1	30
62	First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. <i>Lancet Oncology</i> , The, 2009, 10, 1102-1110.	5.1	28
63	Pharmacogenetics of Target Genes Across the Warfarin Pharmacological Pathway. <i>Clinical Pharmacokinetics</i> , 2006, 45, 1189-1200.	1.6	27
64	Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 53-60.	2.0	27
65	Targeting <i>FGFR1</i> -amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8034-8034.	0.8	27
66	Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokers. <i>Lung Cancer</i> , 2007, 56, 161-166.	0.9	26
67	Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC): Asian subgroup analysis. <i>Annals of Oncology</i> , 2014, 25, 529-536.	0.6	26
68	Assessment of human papillomavirus and Epstein-Barr virus in lung adenocarcinoma. <i>Oncology Reports</i> , 2009, 21, 971-5.	1.2	25
69	A merged lung cancer transcriptome dataset for clinical predictive modeling. <i>Scientific Data</i> , 2018, 5, 180136.	2.4	25
70	First-line afatinib for the treatment of <i>EGFR</i> mutation-positive non-small-cell lung cancer in the "real-world" clinical setting. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591983637.	1.4	25
71	Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2131892.	2.8	25
72	Primary pulmonary lymphoepithelioma-like carcinoma in Singapore. <i>Annals of Thoracic Medicine</i> , 2018, 13, 30.	0.7	22

#	ARTICLE	IF	CITATIONS
73	Electroacupuncture for Refractory Acute Emesis Caused by Chemotherapy. <i>Journal of Alternative and Complementary Medicine</i> , 2006, 12, 963-969.	2.1	21
74	A Decade of Never-smokers Among Lung Cancer Patients—Increasing Trend and Improved Survival. <i>Clinical Lung Cancer</i> , 2018, 19, e539-e550.	1.1	21
75	JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA2-LBA2.	0.8	21
76	Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 5939-5950.	3.2	21
77	Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. <i>Annals of Oncology</i> , 2012, 23, 1010-1016.	0.6	20
78	First-in-human phase I/II open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. , 2021, 9, e002863.		20
79	Bright Aggregation-Induced Emission Dots for Dynamic Tracking and Grading of Patient-Derived Xenografts in Zebrafish. <i>Advanced Functional Materials</i> , 2019, 29, 1901226.	7.8	19
80	An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer. <i>Thyroid</i> , 2020, 30, 1254-1262.	2.4	19
81	Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases. <i>BMC Cancer</i> , 2018, 18, 1198.	1.1	18
82	Phase 1b Trial of Ficlatusumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 532-542.	0.8	17
83	Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC). <i>PLoS ONE</i> , 2019, 14, e0224665.	1.1	17
84	Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 289-296.	0.9	16
85	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. <i>BMC Cancer</i> , 2018, 18, 352.	1.1	16
86	Phase Ib/II study of the PI3K± inhibitor BYL719 in combination with cetuximab in recurrent/metastatic squamous cell cancer of the head and neck (SCCHN).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6044-6044.	0.8	16
87	Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules. <i>PLoS ONE</i> , 2016, 11, e0154316.	1.1	16
88	Fanconi's Anemia in Adulthood: Chemoradiation-Induced Bone Marrow Failure and a Novel FANCA Mutation Identified by Targeted Deep Sequencing. <i>Journal of Clinical Oncology</i> , 2011, 29, e591-e594.	0.8	15
89	Abstract CT150: Phase II study of spartalizumab (PDR001) vs chemotherapy (CT) in patients with recurrent/metastatic nasopharyngeal cancer (NPC). <i>Cancer Research</i> , 2019, 79, CT150-CT150.	0.4	15
90	Detection and prognostic relevance of circulating tumour cells (CTCs) in Asian breast cancers using a label-free microfluidic platform. <i>PLoS ONE</i> , 2019, 14, e0221305.	1.1	14

#	ARTICLE	IF	CITATIONS
91	Paraneoplastic pemphigus resembling linear IgA bullous dermatosis. <i>International Journal of Dermatology</i> , 2006, 45, 1093-1095.	0.5	13
92	Compendiums of cancer transcriptomes for machine learning applications. <i>Scientific Data</i> , 2019, 6, 194.	2.4	13
93	A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. <i>Oncotarget</i> , 2017, 8, 41474-41486.	0.8	13
94	Personalized Treatment Through Detection and Monitoring of Genetic Aberrations in Single Circulating Tumor Cells. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 255-273.	0.8	12
95	Dysfunctional Bronchial Cilia Are a Feature of Chronic Obstructive Pulmonary Disease (COPD). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2021, 18, 657-663.	0.7	12
96	MINIO1.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, S257-S258.	0.5	11
97	Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. <i>Journal of Medical Economics</i> , 2020, 23, 1330-1339.	1.0	11
98	Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study. <i>Oral Oncology</i> , 2021, 115, 105222.	0.8	11
99	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9124-TPS9124.	0.8	11
100	Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1578-1584.	0.6	10
101	Metronomic chemotherapy: A relook at its basis and rationale. <i>Cancer Letters</i> , 2017, 388, 328-333.	3.2	10
102	Interactions between clinical factors, p16, and cyclin-D1 expression and survival outcomes in oropharyngeal and hypopharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1650-1659.	0.9	9
103	Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 698551.	1.3	9
104	Capecitabine and oxaliplatin (XELOX) is safe and effective in patients with advanced gastric cancer. <i>Acta Oncologica</i> , 2007, 46, 1032-1034.	0.8	8
105	Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation. <i>Bone Marrow Transplantation</i> , 2011, 46, 573-579.	1.3	8
106	Reply: The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. <i>Nature Medicine</i> , 2014, 20, 1090-1091.	15.2	8
107	P1.17-07 Neoadjuvant Gefitinib in Resectable Early Stage EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): A Window-of-Opportunity Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, S609-S610.	0.5	8
108	Prognostic Neurotransmitter Receptors Genes Are Associated with Immune Response, Inflammation and Cancer Hallmarks in Brain Tumors. <i>Cancers</i> , 2022, 14, 2544.	1.7	8

#	ARTICLE	IF	CITATIONS
109	Phase II clinical trials in oncology: are we hitting the target?. Expert Review of Anticancer Therapy, 2010, 10, 427-438.	1.1	7
110	A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer, 2010, 67, 325-329.	0.9	7
111	Dynamic Contrast-Enhanced Computed Tomography in Metastatic Nasopharyngeal Carcinoma. Investigative Radiology, 2012, 47, 5-10.	3.5	7
112	Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer. Head and Neck, 2015, 37, 1349-1357.	0.9	7
113	IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. Annals of Oncology, 2018, 29, ix177-ix178.	0.6	7
114	IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. Annals of Oncology, 2019, 30, ii48-ii49.	0.6	7
115	Phase II study of nimotuzumab (TheraCim®) concurrent with cisplatin/radiotherapy in patients with locally advanced head and neck squamous cell carcinoma. Head and Neck, 2021, 43, 1641-1651.	0.9	7
116	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. Lung Cancer, 2021, 155, 127-135.	0.9	6
117	Variable Problems in Lymphomas. Journal of Clinical Oncology, 2005, 23, 8112-8113.	0.8	5
118	Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore. Annals of Oncology, 2018, 29, ix161.	0.6	5
119	Bacillus Calmette-Guérin scar flare after an mRNA SARS-CoV-2 vaccine. Cmaj, 2021, 193, E1178-E1178.	0.9	5
120	Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures. Cancer Immunology, Immunotherapy, 2022, 71, 989-998.	2.0	5
121	Randomized phase III trial of concurrent chemoradiation with or without neoadjuvant gemcitabine, carboplatin, and paclitaxel in locally advanced nasopharyngeal cancer.. Journal of Clinical Oncology, 2014, 32, 6003-6003.	0.8	5
122	Should Screening for DPD Deficiency Be Mandatory before 5-FU Exposure?. Oncology Research and Treatment, 2004, 27, 531-533.	0.8	4
123	Do elderly patients benefit from enrollment into Phase I Trials?. Journal of Geriatric Oncology, 2015, 6, 241-248.	0.5	4
124	MA 12.02 Phase I/II Study of S49076, a MET/AXL/FGFR Inhibitor, Combined with Gefitinib in NSCLC Patients Progressing on EGFR TKI. Journal of Thoracic Oncology, 2017, 12, S1847-S1848.	0.5	4
125	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience. JCO Precision Oncology, 2021, 5, 859-875.	1.5	4
126	Prognostic Matrisomal Gene Panel and Its Association with Immune Cell Infiltration in Head and Neck Carcinomas. Cancers, 2021, 13, 5761.	1.7	4

#	ARTICLE	IF	CITATIONS
127	A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 625-634.	1.9	4
128	Adrenal Insufficiency in Intestinal Obstruction from Carcinomatosis Peritonei—A Factor of Potential Importance in Symptom Palliation. <i>Journal of Pain and Symptom Management</i> , 2005, 29, 411-418.	0.6	3
129	Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis. <i>Journal of Thoracic Oncology</i> , 2009, 4, 988-993.	0.5	3
130	Truth About ERCC1 in Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, e162-e162.	0.8	3
131	'Prechronous' metastasis in clear cell renal cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2011, 5, 181.	0.4	3
132	Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 120-123.	0.7	3
133	Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. <i>Annals of Oncology</i> , 2018, 29, viii525.	0.6	3
134	Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC). , 2020, , .		3
135	Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN). <i>Molecular Cancer Therapeutics</i> , 2015, 14, A46-A46.	1.9	3
136	Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment. <i>Cancer Communications</i> , 2022, , .	3.7	3
137	Life-Threatening Pneumonitis Related to Docetaxel Chemotherapy. <i>Proceedings of Singapore Healthcare</i> , 2015, 24, 54-58.	0.2	2
138	Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma. <i>Annals of Oncology</i> , 2018, 29, viii678.	0.6	2
139	P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers. <i>Journal of Thoracic Oncology</i> , 2018, 13, S463.	0.5	2
140	Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations. <i>International Journal of Clinical Oncology</i> , 2021, 26, 841-850.	1.0	2
141	Ultra-High Throughput Enrichment of Viable Circulating Tumor Cells. <i>IFMBE Proceedings</i> , 2014, , 1-4.	0.2	2
142	Abstract CT203: A phase II trial of ipilimumab in combination with nivolumab in EBV-associated advanced nasopharyngeal carcinoma (NCT03097939). <i>Cancer Research</i> , 2020, 80, CT203-CT203.	0.4	2
143	Cyclin D1 expression in KRAS mutant non-small cell lung cancer—'old wine into new skins. <i>Translational Lung Cancer Research</i> , 2020, 9, 2302-2304.	1.3	2
144	Induction concurrent chemoradiotherapy using Paclitaxel and Carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer—Asian experience. <i>Annals of the Academy of Medicine, Singapore</i> , 2008, 37, 377-82.	0.2	2

#	ARTICLE	IF	CITATIONS
145	A phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. <i>Oncology Reports</i> , 2006, 15, 123.	1.2	1
146	A Phase I trial of weekly docetaxel and topotecan for solid tumors. <i>Acta Oncologica</i> , 2008, 47, 311-315.	0.8	1
147	Nonmyeloablative Allogeneic Stem Cell Transplantation for Nasopharyngeal Carcinoma. <i>Oncologist</i> , 2010, 15, 1192-1197.	1.9	1
148	Matrisomal abnormality: a predictive biomarker for cancer immunotherapy. <i>Annals of Oncology</i> , 2019, 30, vi103.	0.6	1
149	MicroRNA-Profilng Based Screening of Non-small-cell Lung Cancer in Plasma. , 2021, , 295-306.		1
150	Do elderly patients benefit from enrollment in phase I clinical trials?. <i>Journal of Clinical Oncology</i> , 2013, 31, 9509-9509.	0.8	1
151	Molecular detection of ROS1-rearranged circulating tumor cells (CTC) in non-small cell lung cancer (NSCLC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23086-e23086.	0.8	1
152	Concordance of ALK rearrangement patterns between CTCs and tumour in non-small cell lung cancer (NSCLC). <i>Annals of Oncology</i> , 2015, 26, vii113.	0.6	0
153	Clinical outcome of reflex EGFR mutation and ALK fusion testing in patients with non-squamous non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2016, 9, 75-80.	0.7	0
154	Treatment and outcomes of elderly patients (>65 years) with lung adenocarcinoma. <i>European Journal of Cancer</i> , 2016, 60, e17.	1.3	0
155	P3.01-017 Clinical Outcomes of Patients with EGFR T790M + NSCLC on Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2206.	0.5	0
156	A phase I pharmacokinetic study of metronomic vinorelbine and sorafenib using two schedules in Asian non-small cell lung cancer (NSCLC) patients. <i>Annals of Oncology</i> , 2017, 28, x39-x40.	0.6	0
157	EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs). <i>Annals of Oncology</i> , 2017, 28, x127-x128.	0.6	0
158	P2.13-21 MET Addiction Can be Circumvented Through EGFR Inhibition Via AXL in MET-Amplified Primary Resistant EGFR-Mutant NSCLC.. <i>Journal of Thoracic Oncology</i> , 2018, 13, S806.	0.5	0
159	Profiling Circulating Tumour Cells for Clinical Applications. , 0, , .		0
160	Clinicopathological characteristics and outcome of advanced ROS1-positive non-small cell lung cancer in Asian patients. <i>Annals of Oncology</i> , 2019, 30, ii54.	0.6	0
161	JUPITOR-02: Randomized, Double-Blind, Phase 3 Study of Toripalimab or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
162	Complete disease remission in a TP53 and KRAS co-mutated brain oligometastatic lung cancer patient after immuno-chemotherapy and surgical resection: a case report. <i>Translational Lung Cancer Research</i> , 2021, 10, 2298-2305.	1.3	0

#	ARTICLE	IF	CITATIONS
163	Hemoglobin subunit beta (HBB) is a potential biomarker for predicting response to Gefitinib in NSCLC patients. <i>Journal of Integrated OMICS</i> , 2011, 1, .	0.5	0
164	Abstract 1911: A common BIM polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. , 2012, , .		0
165	Docetaxel pharmacogenetics: The influence of <i>RXR</i> and <i>HNF4</i> genetic variations on docetaxel disposition in Asian nasopharyngeal carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2598-2598.	0.8	0
166	Phase I dose escalation study of pan-histone deacetylase (HDAC) inhibitor abexinostat in combination with cisplatin in patients with advanced non-keratinizing nasopharyngeal carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e17059-e17059.	0.8	0
167	Relationship between tumor response with outcomes in EGFR mutation positive (M+) non-small cell lung cancer (NSCLC) treated with tyrosine-kinase inhibitors (TKI).. <i>Journal of Clinical Oncology</i> , 2014, 32, e19101-e19101.	0.8	0
168	Differences in clinical characteristics and overall survival in never-smokers with lung squamous cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e12527-e12527.	0.8	0
169	Abstract 5008: Elucidating HER2 molecular heterogeneity of circulating tumor cells among breast cancer patients. , 2016, , .		0
170	Comparing genomic landscape of early stage, treatment naïve and late stage, drug resistant EGFR-mutant lung adenocarcinomas. <i>Canadian Journal of Biotechnology</i> , 2017, 1, 246-247.	0.3	0
171	Abstract 5060: Establishment and characterization of humanized mouse NPC-PDX model for testing immunotherapy. , 2020, , .		0
172	The case for better hospitalisation selection in cancer patients. <i>Annals of the Academy of Medicine, Singapore</i> , 2021, 50, 880-881.	0.2	0